KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Accumulated Expenses (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 10 years of Other Accumulated Expenses data on record, last reported at $21.7 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 116.08% year-over-year to $21.7 million; the TTM value through Sep 2025 reached $21.7 million, up 116.08%, while the annual FY2024 figure was $9.3 million, 68.65% down from the prior year.
  • Other Accumulated Expenses reached $21.7 million in Q3 2025 per IONS's latest filing, down from $22.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $29.6 million in Q4 2023 and bottomed at $7.5 million in Q4 2022.
  • Average Other Accumulated Expenses over 5 years is $14.0 million, with a median of $10.5 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 292.81% in 2023, then plummeted 68.65% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $12.3 million in 2021, then tumbled by 38.81% to $7.5 million in 2022, then soared by 292.81% to $29.6 million in 2023, then tumbled by 68.65% to $9.3 million in 2024, then surged by 133.66% to $21.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $21.7 million in Q3 2025, $22.8 million in Q2 2025, and $22.3 million in Q1 2025.